LY3295668 erbumine in extensive-stage small-cell lung cancer

• Research type

  Research Study

• Full title

  Phase 1b Study of LY3295668 erbumine Monotherapy in Patients with Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

• IRAS ID

  258852

• Contact name

  Anna Minchom

• Contact email

  Anna.Minchom@icr.ac.uk

• Sponsor organisation

  Eli Lilly and Company

• Eudract number

  2018-003485-14

• Duration of Study in the UK

  1 years, 4 months, 16 days

• Research summary

  Summary of Researh
  The goal of this study is to learn more about the experimental drug LY3295668 erbumine in the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Lung cancer is the leading cause of cancer deaths worldwide. ES-SCLC is a type of SCLC that has spread from the original affected lung. Patients with ES-SCLC are commonly treated with different types of chemotherapy. Most patients respond well to this type of treatment at first, but for many the cancer will come back and can be harder to treat.
  Research has shown that SCLC can continue to grow, even when treated with chemotherapy, because of a group of proteins in the body known as the “Aurora Kinase” enzymes. New treatments are being studied which target one or more of these enzymes including the drug LY3295668 erbumine. Studies have shown that the blocking of one of these enzymes by the drug LY3295668 erbumine may stop the cancer from growing.
  This study is an early phase clinical trial with a goal to finding the best recommended daily dose of the new drug LY3295668 erbumine for the treatment of ES-SCLC. Patients must be at least 18 years of age and have been previously treated for SCLC and have had their cancer grow while on treatment. Patients must be able and willing to undergo a mandatory tumour biopsy prior to entering study treatment. Patients will not receive any other treatment for their cancer while they are receiving study treatment. Approximately 60 patients from the US, EU, Turkey, Korea and Japan will be selected to take part, with 7 participants from the UK.

  Summary of Results
  A lay summary has not been created yet but will be provided when available

• REC name

  London - Central Research Ethics Committee

• REC reference

  19/LO/0548

• Date of REC Opinion

  30 Jul 2019

• REC opinion

  Further Information Favourable Opinion